Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
BEAM

Beam Therapeutics Inc

BEAM

26.40USD-2.35 (-8.17%)Market Closed
Watchlist

Market Summary

USD26.40-2.35
Market Closed
-8.17%

BEAM Alerts

  • 1 major insider sales recently.
  • Losses in recent quarter

BEAM Stock Price

View Fullscreen

BEAM RSI Chart

BEAM Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-6.68

Price/Sales (Trailing)

25.7

EV/EBITDA

-8.21

Price/Free Cashflow

-5.35

BEAM Price/Sales (Trailing)

BEAM Profitability

EBT Margin

-339.23%

Return on Equity

-40.31%

Return on Assets

-24.16%

Free Cashflow Yield

-18.7%

BEAM Fundamentals

BEAM Revenue

Revenue (TTM)

81.6M

Revenue Y/Y

8.82%

Revenue Q/Q

-14.53%

BEAM Earnings

Earnings (TTM)

-313.7M

Earnings Y/Y

12.31%

Earnings Q/Q

-16.08%

Price Action

Last 7 days

2.4%

Last 30 days

15.1%

Last 90 days

12.5%

Trailing 12 Months

-34.8%

How does BEAM drawdown profile look like?

BEAM Financial Health

Current Ratio

5.22

BEAM Investor Care

Shares Dilution (1Y)

12.67%

Diluted EPS (TTM)

-4.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202376.7M80.2M81.6M0
202254.1M56.4M58.7M60.9M
202113.0M25.9M38.9M51.8M
202000024.0K
20190000

Latest Insider Trading transactions for BEAM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 20, 2023
bellon christine
sold
-305,000
30.5
-10,000
chief legal officer
Nov 20, 2023
bellon christine
acquired
72,200
7.22
10,000
chief legal officer
Oct 30, 2023
simon amy
sold
-64,477
18.7
-3,448
chief medical officer
Oct 20, 2023
ciaramella giuseppe
acquired
60,903
0.67
90,900
president and cso
Oct 02, 2023
bellon christine
sold
-8,865
22.85
-388
chief legal officer
Jul 24, 2023
ciaramella giuseppe
sold
-38,604
32.01
-1,206
president and cso
Jul 24, 2023
ciaramella giuseppe
acquired
8,707
7.22
1,206
president and cso
Jul 21, 2023
ciaramella giuseppe
sold
-4,979,690
32.06
-155,324
president and cso
Jul 21, 2023
ciaramella giuseppe
acquired
659,070
7.22
91,284
president and cso
Jul 10, 2023
simon amy
sold
-11,917
30.48
-391
chief medical officer

1–10 of 50

Which funds bought or sold BEAM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Dec 06, 2023
CITIGROUP INC
added
21.48
-441,334
4,752,210
-%
Nov 27, 2023
AllSquare Wealth Management LLC
reduced
-78.57
-14,978
2,886
-%
Nov 24, 2023
DEUTSCHE BANK AG\
added
8.36
-307,690
1,366,020
-%
Nov 21, 2023
COMERICA BANK
new
-
12,939
12,939
-%
Nov 16, 2023
Financial Gravity Asset Management, Inc.
sold off
-100
-31.00
-
-%
Nov 15, 2023
GSA CAPITAL PARTNERS LLP
new
-
283,000
283,000
0.02%
Nov 15, 2023
MORGAN STANLEY
reduced
-37.48
-14,110,500
12,557,200
-%
Nov 15, 2023
Beaird Harris Wealth Management, LLC
reduced
-49.76
-4,188
2,550
-%
Nov 15, 2023
Baker Avenue Asset Management, LP
added
26.09
-37.00
697
-%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
added
22.29
-69,070
806,036
-%

1–10 of 41

Latest Funds Activity

Are funds buying BEAM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BEAM
No. of Funds

Schedule 13G FIlings of Beam Therapeutics Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 22, 2023
farallon capital partners, l.p.
0.4%
306,547
SC 13G
Mar 17, 2023
temasek holdings (private) ltd
5.0%
3,644,573
SC 13G
Feb 14, 2023
farallon capital partners, l.p.
0.0%
0
SC 13G/A
Feb 10, 2023
temasek holdings (private) ltd
4.1%
2,878,297
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.90%
6,273,630
SC 13G/A
Feb 02, 2023
blackrock inc.
7.4%
5,238,280
SC 13G/A
Jul 14, 2022
farallon capital partners, l.p.
0.4%
276,948
SC 13G
Feb 14, 2022
arch venture fund ix, l.p.
8.6%
5,843,039
SC 13G/A
Feb 14, 2022
redmile group, llc
2.8%
1,885,850
SC 13G/A

Recent SEC filings of Beam Therapeutics Inc

View All Filings
Date Filed Form Type Document
Nov 22, 2023
4
Insider Trading
Nov 20, 2023
144
Notice of Insider Sale Intent
Nov 08, 2023
8-K
Current Report
Nov 08, 2023
10-Q
Quarterly Report
Nov 01, 2023
4
Insider Trading
Oct 31, 2023
8-K
Current Report
Oct 30, 2023
144
Notice of Insider Sale Intent
Oct 24, 2023
4
Insider Trading
Oct 19, 2023
8-K
Current Report
Oct 12, 2023
UPLOAD
UPLOAD

Peers (Alternatives to Beam Therapeutics Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.5B
-
5.25% 401813.88%
-3.7K
218.4K
- -102.45%
30.6B
10.7B
8.54% -55.34%
-8.83
2.87
-53.67% -129.46%
21.3B
1.7B
4.15% -23.37%
-41.84
12.38
79.37% 56.87%
17.5B
2.3B
11.05% -8.44%
119.09
7.58
15.05% 75.21%
12.3B
3.6B
0.84% -34.33%
28.84
3.4
8.35% -51.49%
MID-CAP
7.4B
272.9M
35.37% 34.74%
-12.26
27.23
141.38% 4.43%
5.7B
-
14.36% 263.35%
-9.69
48.33
54.84% -12.96%
3.4B
631.9M
-7.32% 48.57%
-23.12
5.44
23.54% 31.53%
3.3B
223.4M
11.28% -10.13%
-16.45
14.86
- -26.24%
2.6B
240.7M
-10.83% -25.35%
-12.52
10.67
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
11.36% -14.92%
24.33
4.33
81.69% -7.29%
661.3M
1.0B
-22.00% -67.89%
-1.2
0.63
-43.15% 58.48%
100.5M
6.4M
- -79.23%
-0.61
15.6
-44.11% 50.48%
37.6M
-
376.67% 112.17%
-0.58
-
- -29.23%
23.7M
-
25.24% 3980.68%
-0.5
-
- -13.74%

Beam Therapeutics Inc News

Latest updates
Barchart08 Dec 202308:25 pm5 hours ago
Barchart08 Dec 202305:37 pm8 hours ago
Nasdaq08 Dec 202304:30 pm9 hours ago
Barchart08 Dec 202304:18 pm9 hours ago
Barchart08 Dec 202302:35 pm11 hours ago
MarketBeat08 Dec 202301:29 pm12 hours ago
Nasdaq08 Dec 202301:26 pm12 hours ago
Investing.com UK08 Dec 202312:20 pm13 hours ago
InvestorsObserver08 Dec 202311:51 am13 hours ago
Barchart08 Dec 202311:10 am14 hours ago
Barchart08 Dec 202310:45 am15 hours ago
Barchart08 Dec 202307:19 am18 hours ago
Barchart08 Dec 202303:00 am22 hours ago
Nasdaq30 Nov 202302:55 pm8 days ago

Financials for Beam Therapeutics Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-14.5%17,193,00020,116,00024,208,00020,037,00015,799,00016,652,0008,432,0006,325,5004,219,0002,112,5006,0006,0006,000162,800319,600476,400633,200790,000498,000
Operating Expenses2.6%125,460,000122,264,000123,136,000109,022,000107,102,00098,618,00084,657,000114,553,00070,397,00058,980,000200,379,00040,805,00037,327,00026,291,00028,361,00026,377,00018,030,00017,657,00013,108,000
  S&GA Expenses3.1%25,410,00024,656,00023,490,00022,681,00021,815,00024,062,00019,247,00017,772,00015,774,00013,403,00010,273,0008,354,0007,502,0006,937,0006,812,0006,160,0005,487,0004,977,0003,929,000
  R&D Expenses2.5%100,050,00097,608,00099,646,00086,341,00085,287,00074,556,00065,410,00096,781,00054,623,00045,577,000190,106,00032,451,00029,825,00019,354,00021,549,00020,217,00012,543,00012,680,0009,179,000
EBITDA Margin----3.19-4.03-4.77--------------
Interest Expenses-44.0%28,00050,00062,00076,00086,000101,000113,000124,000136,000148,000159,000139,000140,000------
Income Taxes----1,010,0002,410,000-----159,000-422,000140,000148,000134,000----
Earnings Before Taxes-----37,349,000-81,665,000---64,707,000-28,118,000----------
EBT Margin----3.39-4.27-4.99--------------
Net Income-16.1%-96,088,000-82,776,000-96,460,000-38,349,000-109,575,000-71,950,000-69,214,000-64,707,000-28,118,000-76,253,000-201,560,000-95,464,000-34,452,000-34,218,000-30,458,000-27,850,000-19,005,000-17,861,000-13,610,000
Net Income Margin100.0%--4.08-4.12-4.75-5.38-4.51-4.60-7.15-10.32-15.72-28.18-8,108-282-127-73.21----
Free Cashflow100.0%--100,847,000-115,832,000-77,452,000-86,283,000-73,920,000211,231,000-11,539,000-2,773,000-48,711,000-50,056,000-32,423,000-24,032,000-25,204,000-30,439,000-19,960,000-18,411,000--
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-4.7%1,2911,3541,3321,3421,3501,4181,4531,4741,157893693452278300323156
  Current Assets-5.0%1,0401,0951,0831,0931,1091,1801,2391,27394167851530820923526095.00
    Cash Equivalents-21.2%17822625023315726629757361221297.0016213812512651.00
  Net PPE-0.5%12812812211611110694.0084.0072.0064.0052.0039.0029.0026.0025.0024.00
Liabilities-5.7%51254257160863661862464830334527120678.0069.0061.0055.00
  Current Liabilities5.2%22021022022423921221921310112910210247.0039.0031.0029.00
Shareholder's Equity-4.0%779812762733714800829827854549422246200231261-
  Retained Earnings-8.3%-1,300-1,200-1,153-1,057-1,019-909-837-768-703-675-599-397-302-267-233-203
  Additional Paid-In Capital3.1%2,1132,0491,9151,7931,7371,7131,6691,5941,5571,2231,0216435024984952.00
Shares Outstanding1.8%79.0078.0074.0071.0070.0070.0069.0068.0066.0062.0060.0057.0050.0049.0031.007.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-6.0%-89.78-84.67-109-69.19-74.50-52.282182.003.00-32.53-38.58-24.30-21.21-22.84-27.39-17.80-16.99-11.35-25.86
  Share Based Compensation-1.7%26.0026.0024.0022.0022.0022.0018.0016.0013.0010.005.007.003.003.003.002.002.002.001.00
Cashflow From Investing75.3%-10.23-41.4825.00113-36.17-1.26-537-77.5076.00-13.14-279-81.4335.0023.00-76.7917.0014.00-95.08-2.35
Cashflow From Financing-65.8%37.0010898.0032.002.0022.0056.0022.003211602531300.00-0.781931.003.00-0.0238.00

BEAM Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
License and collaboration revenue$ 17,193,000$ 15,799,000$ 61,517,000$ 40,883,000
Revenue, Product and Service [Extensible List]us-gaap:LicenseMemberus-gaap:LicenseMemberus-gaap:LicenseMemberus-gaap:LicenseMember
Operating expenses:    
Research and development$ 100,050,000$ 85,287,000$ 297,304,000$ 225,253,000
General and administrative25,410,00021,815,00073,556,00065,124,000
Total operating expenses125,460,000107,102,000370,860,000290,377,000
Loss from operations(108,267,000)(91,303,000)(309,343,000)(249,494,000)
Other income (expense):    
Change in fair value of derivative liabilities4,700,000(4,900,000)9,400,00020,900,000
Change in fair value of non-controlling equity investments(11,221,000)10,431,000(17,870,000)(1,378,000)
Change in fair value of contingent consideration liabilities6,002,000(875,000)7,877,000(543,000)
Interest and other income (expense), net12,698,0004,982,00034,612,0007,686,000
Total other income (expense)12,179,0009,638,00034,019,00026,665,000
Net loss before income taxes(96,088,000)(81,665,000)(275,324,000)(222,829,000)
Provision for income taxes0(2,410,000)0(2,410,000)
Loss from equity method investment (25,500,000) (25,500,000)
Net loss(96,088,000)(109,575,000)(275,324,000)(250,739,000)
Unrealized gain (loss) on marketable securities(9,000)(484,000)406,000(4,624,000)
Comprehensive loss$ (96,097,000)$ (110,059,000)$ (274,918,000)$ (255,363,000)
Net loss per common share, basic$ (1.22)$ (1.56)$ (3.63)$ (3.59)
Net loss per common share, diluted$ (1.22)$ (1.56)$ (3.63)$ (3.59)
Weighted - average common shares outstanding, basic79,024,64770,343,19675,902,61269,758,434
Weighted - average common shares outstanding, diluted79,024,64770,343,19675,902,61269,758,434

BEAM Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 169,049$ 232,767
Marketable securities846,408845,367
Prepaid expenses and other current assets24,08414,762
Total current assets1,039,5411,092,896
Property and equipment, net127,521115,620
Restricted cash8,68012,754
Operating lease right-of-use assets112,140118,513
Other assets2,6521,931
Total assets1,290,5341,341,714
Current liabilities:  
Accounts payable3,1779,029
Accrued expenses and other current liabilities41,76948,059
Derivative liabilities8,90018,300
Current portion of deferred revenue153,484135,974
Current portion of lease liability11,95110,380
Current portion of equipment financing liability1,0841,853
Total current liabilities220,365223,595
Long-term lease liability160,637168,625
Long-term equipment financing liability3041,154
Contingent consideration liabilities4,58612,463
Long-term portion of deferred revenue124,653202,179
Other liabilities1,048224
Total liabilities511,593608,240
Commitments and contingencies (See Note 7, License agreements and Note 8, Collaboration and license agreements)
Stockholders’ equity:  
Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at September 30, 2023 and December 31, 2022, respectively
Common stock, $0.01 par value; 250,000,000 shares authorized, 79,382,032 and 71,277,339 issued and outstanding at September 30, 2023 and December 31, 2022, respectively794712
Additional paid-in capital2,112,8571,792,554
Accumulated other comprehensive (loss) income(2,024)(2,430)
Accumulated deficit(1,332,686)(1,057,362)
Total stockholders' equity778,941733,474
Total liabilities and stockholders' equity$ 1,290,534$ 1,341,714
BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
 CEO
 WEBSITEbeamtx.com
 EMPLOYEES532

Beam Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Beam Therapeutics Inc? What does BEAM stand for in stocks?

BEAM is the stock ticker symbol of Beam Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Beam Therapeutics Inc (BEAM)?

As of Thu Dec 07 2023, market cap of Beam Therapeutics Inc is 2.28 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BEAM stock?

You can check BEAM's fair value in chart. The fair value of Beam Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Beam Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BEAM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Beam Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BEAM is over valued or under valued. Whether Beam Therapeutics Inc is cheap or expensive depends on the assumptions which impact Beam Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BEAM.

What is Beam Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 07 2023, BEAM's PE ratio (Price to Earnings) is -7.28 and Price to Sales (PS) ratio is 27.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BEAM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Beam Therapeutics Inc's stock?

In the past 10 years, Beam Therapeutics Inc has provided -0.082 (multiply by 100 for percentage) rate of return.